Japan Neurology Clinical Trials Market Report 2022 to 2030

Japan Neurology Clinical Trials Market Analysis

$ 3999

The Japan Neurology Clinical Trials market is projected to grow from $325.1 Mn in 2022 to $518.1 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022 - 2030. The market will be driven by the high prevalence of neurological diseases and a robust healthcare system. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis, Pfizer, Eisai Co., Ltd & Daiichi Sankyo.

ID: IN10JPCT005 CATEGORY: Clinical Trials GEOGRAPHY: Japan AUTHOR: Vidhi Upadhyay

Buy Now

Japan Neurology Clinical Trials Market Executive Summary

The Japan Neurology Clinical Trials market is projected to grow from $325.1 Mn in 2022 to $518.1 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022 - 2030. According to research published in the Journal of Alzheimer's Diseases in March 2021 in Japan, there would be between 6.5 million and 7 million individuals with dementia in 2025 and 8.5 million to 11.5 million people with dementia in 2060. Similarly, Alzheimer's disease is responsible for 50-75% of dementia cases in Japan. In Japan, the yearly prevalence of Parkinson's disease (PD) is stated to be 50-80 per 100,000, and it is fast growing since ageing is a key risk factor for PD. As a result, the high prevalence of the neurological disease is likely to raise demand for clinical trials to come up with more drugs targeted to the therapy for those conditions.

Clinical trials in neurology are varied and address a wide range of neurological disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and stroke. These studies are being done to improve patient treatment choices, create novel medicines, and advance our knowledge of the underlying processes of neurological illnesses. Japan has a well-established clinical trial sector and was regarded as a leader in neurology research. A high frequency of neurological illnesses, a competent healthcare system, and a supportive regulatory environment all contribute to Japan's success in this domain. The Japanese government created the Clinical Research Network Japan (CRN), a nationwide network of hospitals and medical institutes that cooperate together on clinical research. The CRN offers clinical trial assistance and resources, such as centralised ethical review and data management services.

Novartis, Pfizer, Biogen, Sanofi, and Eisai were among the worldwide pharmaceutical and biotechnology corporations undertaking neurology clinical studies in Japan. In addition, numerous Japanese pharmaceutical firms, including Takeda, Otsuka, and Astellas, were undertaking neurology clinical studies. In September 2022, Eisai, a Japanese pharmaceutical company, said that its experimental medicine lecanemab had helped halt cognitive deterioration in adults in the early stages of Alzheimer's disease.

Japan Neurology Clinical Trials Market

Market Dynamics

Market Growth Drivers

One significant reason is the country's unusually high frequency of neurological illnesses in comparison to other advanced economies. As a result, there is an increasing desire for innovative treatments and therapies, which is driving investment in clinical research in the area of neurology.

Another driver is Japan's superior healthcare infrastructure and a favourable regulatory framework that fosters clinical research investment. Japan has a well-established clinical trial market, and the government has taken a number of initiatives such as the establishment of Clinical Research Network Japan (CRN), a nationwide network of hospitals and medical institutes to make clinical trials more convenient in the nation as well as faster approval procedures for specific kinds of studies.

Market Restraints

One of the most significant restraints is the ageing population, which may make recruiting subjects for clinical studies more challenging. Moreover, there may be cultural and language challenges that hinder participant recruitment and retention, especially for international organisations conducting trials in Japan. Some firms face the high expense of performing clinical trials in Japan. Additionally, there may be legislative and administrative barriers that make conducting clinical trials in the nation more challenging.

Competitive Landscape

Key Players

Novartis
Pfizer
Biogen
Sanofi
Eisai Co., Ltd (JPN)
Daiichi Sankyo (JPN)
Takeda (JPN)
Otsuka Pharmaceutical CoAstellas (JPN)
Chugai Pharmaceutical (JPN)

Notable Insights

In September 2022, Eisai, a Japanese pharmaceutical company, reported promising trials for a new Alzheimer's drug. Announced that its experimental medicine lecanemab had helped halt cognitive deterioration in adults in the early stages of Alzheimer's disease.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Neurology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.